GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $27.24 and traded as low as $26.55. GENMAB A/S/S shares last traded at $26.90, with a volume of 502,471 shares traded.
GENMAB A/S/S Stock Performance
The stock’s 50-day moving average is $27.24 and its two-hundred day moving average is $28.08.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Further Reading
- Five stocks we like better than GENMAB A/S/S
- EV Stocks and How to Profit from Them
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Are Penny Stocks a Good Fit for Your Portfolio?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Stock Sentiment Analysis: How it Works
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.